Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
-
Women Made Up 51% of New Tech Applicants at BairesDev in 2023
-
TeraWulf Announces Preliminary Full Year 2023 Financial Highlights and Provides 2024 Guidance
-
Survey Reveals Employers Prioritize Holistic Wellness Over Price When Selecting Employee Benefits
-
Lettuce Financial Launches Solution to Democratize Accounting and Tax Services for Solopreneurs; Announces $6 Million in Seed Funding
-
Solid Biosciences to Participate at Upcoming Investor Conferences
-
American Oncology Network Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call
-
Iterum Therapeutics Provides Business Update
-
Syra Health to Present at the Life Science Investor Forum March 7th
-
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
-
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
-
insightsoftware Wins Dresner Technology Innovation Award for Embedded Business Intelligence
-
CB Insights Ranks Verana Health as a Leader in EHR-based Patient Recruitment Market
-
The Oncology Institute Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call
-
Intermex and PickTrace join forces to help agriculture workers send money cross-border
-
Adlucent Unveils BEACON Application on Google Cloud Marketplace, Expanding Client Solutions
-
Faruqi & Faruqi, LLP Announces Pendency of Class Action Involving Purchasers of Peloton Interactive, Inc. Securities
-
Dimensional Fund Advisors Ltd. : Form 8.3 - TRITAX BIG BOX REIT PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRENT COMMUNICATIONS PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Redrow plc - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - MONDI PLC - Ordinary Shares
-
Correction: Dimensional Fund Advisors Ltd. : Form 8.3 - DS SMITH PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - DS SMITH PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Direct Line Insurance Group plc - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - CUSTODIAN PROPERTY INCOME RE - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Currys plc - Ordinary Shares
-
Transactions by persons discharging managerial responsibilities and/or persons closely associated
-
Dimensional Fund Advisors Ltd. : Form 8.3 - BARRATT DEVELOPMENTS PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - AGEAS - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - ABRDN PROPERTY INCOME TRUST - Ordinary Shares
-
The Shyft Group Achieves Ford Pro Upfitter Designation
-
Fixing of coupon rates - Nykredit Realkredit A/S
-
Delivery Drivers to Benefit from In-Vehicle Cooling Systems from Utilimaster®
-
Form 8.3 - Smart Metering Systems plc
-
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
-
Else Nutrition Increases Canadian Market Penetration with Premier Ontario Retail Partner
-
Abercrombie & Fitch Co. Reports Fourth Quarter and Full Year Results
-
Ocugen to Present at Investing in Cures Summit
-
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
-
Bowlin Travel Centers, Inc. Announces Closing of Issuer Tender Offer
-
Amesite Announces Launch of Active Shooter Preparedness App with World Renowned Expert Chris Grollnek
-
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
-
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
-
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
-
Nexxen Reports Results for the Fourth Quarter and Year Ended December 31, 2023
-
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Abercrombie & Fitch Co. Reports Fourth Quarter and Full Year Results
-
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
-
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
-
23andMe Launches New Genetic Reports on Common Forms of Cancer
